The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.

Exclusion Criteria

• •1. Patients previously treated with SIMLANDI™ or another high-concentration adalimumab biosimilar.
• •2. Patients that, in the opinion of the investigator, have any condition that may impair their ability to participate in the study.
• •3. Any current or history of any condition that, in the opinion of the investigator, participation in the study may increase the risk to the patient.
• •4. Patients for whom treatment with adalimumab may be contraindicated (e.g., patients with demyelinating disorders).
• •5. Patients with moderate to severe heart failure, as indicated by New York Heart Association (NYHA) class \>= 3.
• •6. Patients with severe infections such as sepsis, tuberculosis, or opportunistic infections.
• •7. Patients with history of recurrent infection or with underlying conditions which may predispose them to infections.
• •8. Patients with known hypersensitivity to SIMLANDI™ or its excipients.
• •9. Patients who are unable to secure reimbursement for SIMLANDI™.
• •10. Patient anticipates not being available for follow-up assessments as required for adequate management.
• •11. Active participation in or enrollment in an interventional trial.
• •12. Patient or patient's legal/authorized representative cannot or will not sign informed consent.